切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2025, Vol. 11 ›› Issue (04) : 397 -401. doi: 10.3877/cma.j.issn.2096-1537.2025.04.010

综述

亚甲蓝在脓毒症休克治疗中的研究进展
罗竹, 孙忆莼, 徐静媛()   
  1. 210009 南京,江苏省重症医学重点实验室 东南大学医学院 东南大学附属中大医院重症医学科
  • 收稿日期:2024-04-25 出版日期:2025-11-28
  • 通信作者: 徐静媛
  • 基金资助:
    国家自然科学基金项目(82272211)

Research progress of methylene blue in septic shock

Zhu Luo, Yichun Sun, Jingyuan Xu()   

  1. Jiangsu Provincial Key Laboratory of Critical Care Medicine, Department of Critical Care Medicine, Zhongda Hospital, School of Clinical Medicine, Southeast University, Nanjing 210009, China
  • Received:2024-04-25 Published:2025-11-28
  • Corresponding author: Jingyuan Xu
引用本文:

罗竹, 孙忆莼, 徐静媛. 亚甲蓝在脓毒症休克治疗中的研究进展[J/OL]. 中华重症医学电子杂志, 2025, 11(04): 397-401.

Zhu Luo, Yichun Sun, Jingyuan Xu. Research progress of methylene blue in septic shock[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2025, 11(04): 397-401.

脓毒症休克是威胁人类生命健康的重要疾病之一,尽管研究不断深入,但其发病率和病死率依旧居高不下。亚甲蓝作为非儿茶酚胺类缩血管药物,已有多项研究表明其可以提高患者平均动脉压,减少儿茶酚胺类缩血管药物使用剂量,降低脓毒症休克患者的病死率,然而结论并未统一。本文就亚甲蓝在脓毒症休克中的治疗作用展开综述。

Septic shock is one of the most important threats to human life and health. Despite ongoing researches, the morbidity and mortality remain high. As a non-catecholamine-based vasoconstrictor, methylene blue has been shown in many studies to increase mean arterial pressure, reduce the need of catecholamine vasopressors and reduce the mortality of septic shock. However, these findings have not been consistently conclusive. This article reviewed the therapeutic effect of methylene blue in septic shock in this manuscript.

1
Bauer M, Gerlach H, Vogelmann T, et al. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis [J]. Crit Care, 2020, 24(1): 239.
2
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [J]. JAMA, 2016, 315(8): 801-810.
3
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 [J]. Intensive Care Med, 2021, 47(11): 1181-1247.
4
Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock [J]. Lancet, 2018, 392 (10141): 75-87.
5
Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress [J]. J Intensive Care Med, 2009, 24(5): 293-316.
6
Daff S. NO synthase: structures and mechanisms [J]. Nitric Oxide, 2010, 23(1): 1-11.
7
Tatsumi R, Wuollet AL, Tabata K, et al. A role for calcium-calmodulin in regulating nitric oxide production during skeletal muscle satellite cell activation [J]. Am J Physiol Cell Physiol, 2009, 296(4): C922-C929.
8
Salemme E, Diano S, Maharajan P, et al. Nitric oxide, a neuronal messenger. Its role in the hippocampus neuronal plasticity [J]. Riv Biol, 1996, 89(1): 87-107.
9
Izumi Y, Clifford DB, Zorumski CF. Inhibition of long-term potentiation by NMDA-mediated nitric oxide release [J]. Science, 1992, 257(5074): 1273-1276.
10
Handy RL, Wallace P, Moore PK. Inhibition of nitric oxide synthase by isothioureas: cardiovascular and antinociceptive effects [J]. Pharmacol Biochem Behav, 1996, 55(2): 179-184.
11
Togashi H, Sakuma I, Yoshioka M, et al. A central nervous system action of nitric oxide in blood pressure regulation [J]. J Pharmacol Exp Ther, 1992, 262(1): 343-347.
12
Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location [J]. Annu Rev Physiol, 2002, 64: 749-774.
13
Zeiher AM, Fisslthaler B, Schray-Utz B, et al. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells [J]. Circ Res, 1995, 76(6): 980-986.
14
Alheid U, Frölich JC, Förstermann U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets [J]. Thromb Res, 1987, 47(5): 561-571.
15
Kurihara N, Alfie ME, Sigmon DH, et al. Role of nNOS in blood pressure regulation in eNOS null mutant mice [J]. Hypertension, 1998, 32(5): 856-861.
16
Nathan CF, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity [J]. Curr Opin Immunol, 1991, 3(1): 65-70.
17
MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions [J]. Biochem Biophys Res Commun, 1993, 196(3): 1330-1334.
18
Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote [J]. J Med Toxicol, 2013, 9(3): 242-249.
19
Lambden S, Creagh-Brown BC, Hunt J, et al. Definitions and pathophysiology of vasoplegic shock [J]. Crit Care, 2018, 22(1): 174.
20
Carvajal JA, Germain AM, Huidobro-Toro JP, et al. Molecular mechanism of cGMP-mediated smooth muscle relaxation [J]. J Cell Physiol, 2000, 184(3): 409-420.
21
Cobb JP, Danner RL. Nitric oxide and septic shock [J]. JAMA, 1996, 275 (15): 1192-1196.
22
Forstermann U, Sessa W. Nitric oxide synthases: regulation and function [J]. Eur Heart J, 2012, 33(7): 829-837.
23
Cauwels A. Nitric oxide in shock [J]. Kidney Int, 2007, 72: 557-565.
24
Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls [J]. Cell, 1994, 78: 915-918.
25
de Belder AJ, Radomski MW, Why HJ, et al. Nitric oxide synthase activities in human myocardium [J]. Lancet, 1993, 341: 84-85.
26
Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger [J]. Ann Intern Med, 1994, 120: 227-237.
27
Vallance P, Benjamin N, Collier J. The effect of endothelium-derived nitric oxide on ex vivo whole blood platelet aggregation in man [J]. Eur J Clin Pharmacol, 1992, 42(1): 37-41.
28
Evgenov OV, Bjertnaes LJ. Administration of methylene blue in human septic shock: renaissance of an old drug? [J]. Crit Care Med, 2003, 31(5): 1601-1602.
29
Tchen S, Sullivan JB. Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock [J]. J Crit Care, 2020, 57: 148-156.
30
Ibarra-Estrada M, Kattan E, Aguilera-González P, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial [J]. Crit Care, 2023, 27(1): 110.
31
Belletti A, Musu M, Silvetti S, et al. Non-Adrenergic Vasopressors in Patients with or at Risk for Vasodilatory Shock. A systematic review and Meta-analysis of randomized trials [J]. PLoS One, 2015, 10(11): e0142605.
32
Zhao CC, Zhai YJ, Hu ZJ, et al. Efficacy and safety of methylene blue in patients with vasodilatory shock: a systematic review and meta-analysis [J]. Front Med (Lausanne), 2022, 9: 950596.
33
Ballarin RS, Lazzarin T, Zornoff L, et al. Methylene blue in sepsis and septic shock: a systematic review and meta-analysis [J]. Front Med (Lausanne), 2024, 11: 1366062.
34
Fernando SM, Tran A, Soliman K, et al. Methylene blue in septic shock: a systematic review and Meta-analysis [J]. Crit Care Explor, 2024, 6(7): e1110.
35
Pluta MP, Putowski Z, Czempik PF, et al. Successful use of methylene blue in catecholamine-resistant septic shock: a case report and short literature review [J]. Int J Mol Sci, 2023, 24(13): 10772.
36
Memis D, Karamanlioglu B, Yuksel M, et al. The influence of methylene blue infusion on cytokine levels during severe sepsis [J]. Anaesth Intensive Care, 2002, 30(6): 755-762.
37
Kirov MY, Evgenov OV, Evgenov NV, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study[J]. Crit Care Med, 2001, 29(10): 1860-1867.
38
Weingartner R, Oliveira E, Oliveira ES, et al. Blockade of the action of nitric oxide in human septic shock increases systemic vascular resistance and has detrimental effects on pulmonary function after a short infusion of methylene blue [J]. Braz J Med BiolRes, 1999, 32(12): 1505-1513.
39
Donati A, Conti G, Loggi S, et al. Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? [J]. Crit Care Med, 2002, 30(10): 2271-2277.
40
Brown G, Frankl D, Phang T. Continuous infusion of methylene blue for septic shock [J]. Postgrad Med J, 1996, 72(852): 612-614.
41
Park BK, Shim TS, Lim CM, et al. The effects of methylene blue on hemodynamic parameters and cytokine levels in refractory septic shock [J]. Korean J Intern Med, 2005, 20(2): 123-128.
42
Andresen M, Dougnac A, Diaz O, et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange [J]. J Crit Care, 1998, 13(4): 164-168.
43
Gachot B, Bedos JP, Veber B, et al. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock [J]. Intensive Care Med, 1995, 21(12): 1027-1031.
44
Dumbarton TC, Minor S, Yeung CK, et al. Prolonged methylene blue infusion in refractory septicshock: a case report [J]. Can J Anesth, 2011, 58(4): 401-405.
45
Fernandes D, da Silva-Santos JE, Duma D, et al. Nitric oxide dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity [J]. Mol Pharmacol, 2006, 69(3): 983-990.
46
Puntillo F, Giglio M, Pasqualucci A, et al. Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review [J]. Adv Ther, 2020, 37(9): 3692-3706.
47
薛晋芳, 娄熙冉, 陈国兵. 亚甲蓝治疗脓毒症及脓毒性休克的研究进展 [J]. 中华危重病急救医学, 2021, 33(11): 1384-1387.
48
Juffermans NP, Vervloet MG, Daemen-Gubbels CR, et al. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock [J]. Nitric Oxide, 2010, 22(4): 275-280.
49
Rutledge C, Brown B, Benner K, et al. A novel use of methylene blue in the pediatric ICU [J]. Pediatrics, 2015, 136(4): e1030-e1034.
[1] 中华医学会超声医学分会, 中国研究型医院肿瘤介入治疗委员会, 中国妇幼保健协会乳腺保健专业委员会, 中华医学会肿瘤学分会乳腺癌专业委员会, 中国抗癌协会乳腺癌专业委员会, 中国人体健康科技促进会乳腺专业委员会. 无手术适应证乳腺癌消融治疗专家共识(2025版)[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(01): 1-8.
[2] 董晓培, 袁洋, 李健斌, 宋华, 李凡, 郝艺, 边莉, 王涛, 江泽飞, 张少华. 激素受体阳性、HER-2阴性乳腺癌首发单纯骨转移患者不同一线治疗方式的预后分析[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(01): 25-33.
[3] 栗家兴, 程紫轩, 吕欣悦, 王江芬, 张晶晶, 张亚芬. 肿瘤浸润淋巴细胞在乳腺癌免疫治疗中的作用及其预后预测价值[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(01): 49-54.
[4] 刘恒, 何亦龙, 袁蕊, 刘燕燕, 卢帅, 公茂琪, 查晔军, 蒋协远. 免疫与基质调节细胞治疗创伤性异位骨化的实验研究[J/OL]. 中华损伤与修复杂志(电子版), 2026, 21(01): 47-53.
[5] 李广鑫, 权慧娟, 高志娟, 李良, 王肖君, 曹玉庆. 腹腔镜急诊切除与支架置入限期切除治疗梗阻性结直肠癌的临床效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(02): 142-145.
[6] 李坚, 张伟, 曾少杰, 母德安. 经皮穿刺消融治疗与腹腔镜肝脏切除术治疗早期肝内胆管癌的临床效果对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(02): 187-190.
[7] 杨宇尘, 陈拥军. 三维可视化技术在肝癌转化治疗辅助决策中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 10-15.
[8] 刘建平, 姚灿开. 肝癌转化治疗策略选择和手术时机[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 16-20.
[9] 尹鹏飞, 吴堃, 王槐志, 蔡磊. 肝癌免疫治疗策略及其在围手术期中应用进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 21-27.
[10] 张龙, 徐伟, 孙善柯, 李文柱, 李俊达, 池涌泉, 宋进华, 王学浩, 成峰, 饶建华. 载药微球经动脉栓塞化疗在巨块型肝癌转化治疗中的疗效及安全性[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 28-35.
[11] 钟文卿, 韩冰. 基于术前CT影像数据构建肝癌患者生存期Nomogram预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 53-58.
[12] 沈宏年, 陆含笑, 张硕, 姜东林, 向文, 项洁, 杨军. 非酒精性脂肪性肝病相关肝癌的临床诊治单中心分析[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 95-100.
[13] 耿钦, 李婧, 康强, 柯阳, 李越华. 肝右后叶包膜下脂肪瘤诊治并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 108-113.
[14] 李鹏, 张维桢, 武国帅, 马伊凡, 张灵强. 超声造影在胰腺疾病中的应用研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 119-123.
[15] 慈娟娟, 吴俊成, 朱琴琴. 肝硬化合并食管胃静脉曲张破裂出血患者内镜治疗后再出血风险列线图的构建与验证[J/OL]. 中华消化病与影像杂志(电子版), 2026, 16(01): 47-52.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?